A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease^*

References

• Locatelli F, Aljama P, Bárány P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19:ii1–ii471. Locatelli F, Aljama P, Bárány P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19:ii1–ii47
   PubMed Web of Science ®Google Scholar
• Wazny L, Stojimirovic B, Heidenheim P, et al. Factors influencing erythropoietin compliance in PD patients. Am J Kidney Dis 2002;40:623–82. Wazny L, Stojimirovic B, Heidenheim P, et al. Factors influencing erythropoietin compliance in PD patients. Am J Kidney Dis 2002;40:623–8
   PubMed Web of Science ®Google Scholar
• NeoRecormon (epoetin beta) therapeutic goods administration approved product information. Roche Products Pty Ltd, 2008. Available from: http://www.roche-australia.com/downloads/neorecormon-epoetin-beta-pi.cfm [last accessed 10 April 2008]3. NeoRecormon (epoetin beta) therapeutic goods administration approved product information. Roche Products Pty Ltd, 2008. Available from: http://www.roche-australia.com/downloads/neorecormon-epoetin-beta-pi.cfm [last accessed 10 April 2008]
   Google Scholar
• Aranesp (darbepoetin alfa) therapeutic goods administration approved product information. Amgen Australia Pty Ltd, 2007. Available from: http://www.pbs.gov.au/pi/anparani10208.pdf [last accessed 10 April 2008]4. Aranesp (darbepoetin alfa) therapeutic goods administration approved product information. Amgen Australia Pty Ltd, 2007. Available from: http://www.pbs.gov.au/pi/anparani10208.pdf [last accessed 10 April 2008]
   Google Scholar
• McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires, 2nd ed. New York: Oxford University Press; 19965. McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires, 2nd ed. New York: Oxford University Press; 1996
   Google Scholar
• Turk C, Melzack Reditors.Handbook of pain assessment, 2nd ed. New York: Guilford Press; 20016. Turk C, Melzack Reditors.Handbook of pain assessment, 2nd ed. New York: Guilford Press; 2001
   Google Scholar
• Jones B, Kenward M. Design and analysis of cross-over trials. London: Chapman and Hall; 19897. Jones B, Kenward M. Design and analysis of cross-over trials. London: Chapman and Hall; 1989
   Google Scholar
• Senn S. Cross-over trials in clinical research. Chichester: Wiley; 19938. Senn S. Cross-over trials in clinical research. Chichester: Wiley; 1993
   Google Scholar
• Koch G. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 1972;28:577–849. Koch G. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 1972;28:577–84
   PubMed Web of Science ®Google Scholar
• Choukroun G, Gelu-Mantoulet S, Rouanet S, et al. Pain at the injection site: results of the first cross-over study comparing epoetin beta and darbepoetin alfa administered subcutaneously in health volunteers. Poster presented at the XL-II European Renal Association-European Dialysis and Transplantation Association (ERA-EDTA) Congress; June 4–7, 2005, Istanbul, Turkey [abstract 2005 MP187]10. Choukroun G, Gelu-Mantoulet S, Rouanet S, et al. Pain at the injection site: results of the first cross-over study comparing epoetin beta and darbepoetin alfa administered subcutaneously in health volunteers. Poster presented at the XL-II European Renal Association-European Dialysis and Transplantation Association (ERA-EDTA) Congress; June 4–7, 2005, Istanbul, Turkey [abstract 2005 MP187]
   Google Scholar
• Schmitt CP, Nau B, Brummer C, et al. Increased injection site pain with darbepoetin-alpha compared to epoetin-beta in paediatric dialysis patients. Nephrol Dial Transplant 2006;21:3520–411. Schmitt CP, Nau B, Brummer C, et al. Increased injection site pain with darbepoetin-alpha compared to epoetin-beta in paediatric dialysis patients. Nephrol Dial Transplant 2006;21:3520–4
   PubMed Web of Science ®Google Scholar
• ter Wee P, de Koter Y, van Vliet M, et al. Immediate pain sensation is less with sc NeoRecormon compared to sc Aranesp. Poster presented at the World Congress of Nephrology; April 21–25, 2007, Rio de Janeiro, Brazil [abstract T-PO-1377]12. ter Wee P, de Koter Y, van Vliet M, et al. Immediate pain sensation is less with sc NeoRecormon compared to sc Aranesp. Poster presented at the World Congress of Nephrology; April 21–25, 2007, Rio de Janeiro, Brazil [abstract T-PO-1377]
   Google Scholar
• Veys N, Dhondt A, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta. Clin Nephrol 1998;49:41–413. Veys N, Dhondt A, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta. Clin Nephrol 1998;49:41–4
   PubMed Web of Science ®Google Scholar
• Pannier A, Jordan P, Dougherty F, et al. Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator compared with darbepoetin alfa. Curr Med Res Opin 2007;23:3025–3214. Pannier A, Jordan P, Dougherty F, et al. Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator compared with darbepoetin alfa. Curr Med Res Opin 2007;23:3025–32
   PubMed Web of Science ®Google Scholar
• Granolleras C, Leskopf W, Shaldon S, et al. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study. Clin Nephrol 1991;36:294–815. Granolleras C, Leskopf W, Shaldon S, et al. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study. Clin Nephrol 1991;36:294–8
   PubMed Web of Science ®Google Scholar